• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

14.13 +2.09 (+17.36%)
Streaming Delayed Price Updated: 2:11 PM EDT, Sep 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 433,565
Open 13.60
Bid (Size) 14.09 (700)
Ask (Size) 14.17 (100)
Prev. Close 12.04
Today's Range 13.51 - 14.23
52wk Range 9.770 - 18.30
Shares Outstanding 871,256,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy ↗
Today 13:02 EDT
HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The... 
Via MarketBeat
News headline image
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
Today 0:00 EDT
From HUTCHMED (China) Limited
Via GlobeNewswire

Performance

YTD
+3.5%
+3.5%
1 Month
+22.3%
+22.3%
3 Month
+24.9%
+24.9%
6 Month
+3.6%
+3.6%
1 Year
-7.8%
-7.8%

More News

Read More
News headline image
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
August 30, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
August 27, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
August 16, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED H1 Earnings Call Highlights ↗
July 30, 2026
Via MarketBeat
Topics Earnings
News headline image
HUTCHMED Reports 2026 Interim Results
July 30, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
July 02, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2026 Half-Year Financial Results
June 30, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
June 24, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
June 11, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
May 21, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
May 21, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
April 29, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
April 23, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
April 08, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
March 22, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
March 09, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
March 06, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Reports 2025 Full Year Results and Business Updates
March 05, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors
March 04, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2025 Final Results
February 06, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
January 13, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
January 06, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?
Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.
What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?
HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?
The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market
What is the current price of HUTCHMED (China) Limited - American Depositary Shares?
The current price of HUTCHMED (China) Limited - American Depositary Shares is 14.13
When was HUTCHMED (China) Limited - American Depositary Shares last traded?
The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 09/03/26 02:11 PM ET
What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?
The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 12.31B
How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?
HUTCHMED (China) Limited - American Depositary Shares has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap